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Novel antibody-drug conjugates against HER2 are showing high activity in HER2-negative breast cancer (BC) with low HER2
expression (i.e., 1+ or 2+ and lack of ERBB2 amplification). However, the clinical and molecular features of HER2-low BC are yet to
be elucidated. Here, we collected retrospective clinicopathological and PAM50 data from 3,689 patients with HER2-negative disease
and made the following observations. First, the proportion of HER2-low was higher in HR-positive disease (65.4%) than triple-
negative BC (TNBC, 36.6%). Second, within HR-positive disease, ERBB2 and luminal-related genes were more expressed in HER2-low
than HER2 0. In contrast, no gene was found differentially expressed in TNBC according to HER2 expression. Third, within HER2-low,
ERBB2 levels were higher in HR-positive disease than TNBC. Fourth, HER2-low was not associated with overall survival in HR-positive
disease and TNBC. Finally, the reproducibility of HER2-low among pathologists was suboptimal. This study emphasizes the large
biological heterogeneity of HER2-low BC, and the need to implement reproducible and sensitive assays to measure low HER2
expression.
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INTRODUCTION
HER2-positive breast cancer is currently defined according to the
ASCO/CAP guidelines using immunohistochemistry (IHC) and/or
in situ hybridization (ISH)-based techniques1,2. These guidelines
identify a tumor as HER2-positive when there is a complete and
intense circumferential HER2 IHC staining in ≥10% of cells (score
3+) and/or the gene is amplified with an HER2/CEP17 ratio ≥2.0
and an average HER2 gene (ERBB2) copy number ≥4.0 signals/cell
using ISH-based techniques1. In breast cancer, 10–20% of tumors
are HER2-positive and 80–90% are HER2-negative3,4.
Within HER2-negative disease, substantial heterogeneity exists
regarding the expression of hormone receptors (HR) and HER2. For
example, HER2-negative tumors can express some protein level of
HER2 by IHC5 (i.e., 1+ or 2+ and lack of ERBB2 amplification by
in situ hybridization techniques) and are identified as HER2-low.
Traditionally, patients with HER2-low-expressing tumors do not
seem to benefit from HER2-targeted therapies, such as 1-year of
adjuvant trastuzumab6. However, two HER2-directed antibody-
drug conjugates (ADC) with chemotherapeutics, namely trastuzu-
mab deruxtecan (T-DXd) and trastuzumab duocarmazine (SYD985)
have shown very promising therapeutic activity in patients with
HER2-low breast cancer7–9. A large pivotal randomized phase III
trial of T-DXd in patients with pretreated HER2-low metastatic
breast cancer is underway (i.e., NCT03734029/DESTINY-Breast04).
Owing to the recent and increased interest in the HER2-low
group, there is an urgent need to better understand its
clinicopathological and molecular features. Thus, we decided to
collect clinicopathological and PAM50 gene expression data from
multiple datasets10–17 of HER2-negative disease and compare
many features between HER2-low and HER2 0. Analyses were
focused on the overall population and according to hormone
receptor (HR) status and HER2 IHC expression.
RESULTS
Clinicopathological characteristics of HER2-low disease
Thirteen independent datasets for a total of 3,689 patients with
HER2-negative breast cancer were explored (Fig. 1). Overall, 1,486
(40.3%) patients had HER2 0 tumors, 1,489 (40.4%) had HER2 1+
tumors and 714 (19.3%) had HER2 2+ tumors. Clinicopathological
and gene expression data (when available) were largely obtained
from primary disease (71.1% in HER2-low and 73.7% in HER2 0).
According to HR status, 2,962 (80.8%) patients had HR-positive
disease and 706 (19.2%) had triple-negative breast cancer (TNBC).
HER2-low tumors were more frequently found within HR-
positive disease compared to TNBC (65.4% vs. 36.5%, p < 0.001;
Fig. 2). More specifically, HR-positive disease was characterized by
higher rates of IHC 1+ and 2+ tumors, compared to TNBC (43.8%
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vs. 26.8% and 21.6% vs. 9.8%, respectively, p < 0.001; Fig. 2). In
terms of other clinicopathological variables, HER2-low tumors
presented larger primary tumor sizes (p= 0.007) and more nodal
involvement (p= 0.010) compared to HER2 0 tumors (Table 1 and
Supplementary Table 1). No male patient was observed within the
HER2 0 cohort, compared to the 15 cases observed in the HER2-
low subset (p= 0.001). The median age at diagnosis was higher
for the HER2-low tumors compared to HER2 0 (59 vs. 55 years, p=
0.003). No statistically significant differences were observed in
terms of menopausal status (p= 0.898), histological grade (p=
0.175), Ki67 IHC scores (p= 0.092 using a 14% cut-off) and
percentage of stromal tumor-infiltrating lymphocytes (TILs) (p=
0.218), although TILs’ levels were differently distributed according
to HER2 IHC levels (p= 0.033) and were higher in HER2 2+
(median: 5; interquartile range [IQR] 1–5) compared to 1+
(median: 1; IQR 1–5; p= 0.035) and 0 (median: 1; IQR 1–5; p=
0.035).
Reproducibility of the HER2-low classification
To evaluate the reproducibility of HER2 IHC scoring among
pathologists, we scanned 200 HER2 IHC stained slides from 100
independent cases of the Hospital Clinic case series. The images
were representative of the 4 HER2 IHC categories (i.e., 0, 1+, 2+
and 3+). Five breast cancer-specialized pathologists (BG, ES, RF,
GP, and VP), coming from four different institutions (Clinic, VHIO,
VHV, and Campus Bio-Medico), revised and scored the 100 cases
Fig. 1 STROBE flow-chart. Flow-chart resuming the patient selection process, showing causes for exclusion and the number of patients with
available data for the main analyses presented in the study. GEICAM Grupo Español de Investigación en Cáncer de Mama, CIBOMA Coalición
Iberoamericana de Investigación en Oncología Mamaria, VHIO Vall d’Hebron Institute of Oncology, SOLTI Solid Tumor Intensification Group,
IHC immunohistochemistry, ISH in-situ hybridization, HR hormone receptors.
Fig. 2 Hormone receptor status, HER2-low status, and IHC scores distributions within the HER2-negative population. HR hormone
receptors, IHC immunohistochemistry, ISH in situ hybridization (including either FISH, SISH, and CISH).
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Table 1. Population characteristics according to HER2 status.
Demographics HER2-negative pa
HER2 0 HER2-low Overall population
N % N % N %
1,486 40.3 2,203 59.7 3,689 100
Age at diagnosis (years)
Median 55 59 58 0.003
IQR 46–65 49–67 48–67
Min–max 24–93 26–96 24–96
Pts with available data 259 27.4 685 72.6 944 100
Sex
Male 0 0 15 0.7 15 0.4 0.001
Female 1,486 100 2,187 99.3 3,673 99.6
Total 1,486 40.3 2,202 59.7 3,688 100
Menopaual status
Pre/perimenopausal 385 37.3 660 37.1 1,045 37.2 0.898
Postmenopausal 646 62.7 1,119 62.9 1,765 62.8
Total 1,031 36.7 1,779 63.3 2,810 100
Biospecimen
Primary lesion 1,000 73.7 1,382 71.1 2,382 72.1 0.096
Other lesion 357 34.6 563 28.9 920 27.9
Total 1,357 41.1 1,945 58.9 3,302 100
Histotype
Ductal 639 70.8 1,214 74.3 1,853 73 0.175
Lobular 194 21.5 314 19.2 508 20
Other 69 7.6 107 6.5 176 6.9
Total 902 35.6 1,635 64.4 2,537 100
T
1 509 55.8 807 48.7 1,316 51.2 0.007
2 294 32.2 618 37.3 912 35.5
3 71 7.8 142 8.6 213 8.3
4 38 4.2 89 5.4 127 4.9
Total 912 35.5 1,656 64.5 2,568 100
N
0 556 58.8 937 55.6 1,493 56.8 0.01
1 272 28.8 464 27.6 736 28
2 71 7.5 148 8.8 219 8.3
3 46 4.9 135 8 181 6.9
Total 945 35.9 1,684 64.1 2,629 100
ER
Positive 983 67 1,894 87.1 2,877 79 <0.001
Negative 484 33 280 12.9 764 21
Total 1,467 40.3 2,174 59.7 3,641 100
PgR
Positive 789 54.7 1,542 71.8 2,331 64.9 <0.001
Negative 654 45.3 606 28.2 1260 35.1
Total 1,443 40.2 2,148 59.8 3,591 100
G
1 67 8.8 139 10.6 206 9.9 0.0499
2 272 35.6 514 39.1 786 37.8
3 426 55.7 660 50.3 1086 52.3
Total 765 36.8 1,313 63.2 2,078 100
Ki67
Median 16 18 18 0.892
IQR 9–30 10–27 10–27
Min–max 0.5–95 0.5–95 0.5–95
Pts with available data 433 36.4 756 63.6 1,189 100
≤14% 190 43.9 294 38.9 484 40.7 0.092
>14% 243 56.1 462 61.1 705 59.3
<20% 236 54.5 411 54.4 647 54.4 0.963
≥20% 197 45.5 345 45.6 542 45.6
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in a blinded fashion. Overall, 35 discordant cases (35%) were
observed. The discordances were between IHC 1+ vs. 0 (n= 15),
1+ vs. 2+ (n= 12), 2+ vs. 0 (n= 1), 3+ vs. 1+ (n= 1), and 3+ vs.
2+ (n= 6) scores. In most cases (25 of 35, 71.4%), only one
pathologist was discordant with the others. The multi-rater overall
kappa concordance score was 0.79 (p < 0.001), which is considered
a substantial agreement. The kappa scores according to the HER2
IHC categories 0, 1+, 2+, and 3+ were 0.82 (almost perfect
agreement), 0.67 (substantial agreement), 0.74 (substantial agree-
ment) and 0.92 (almost perfect agreement), respectively (p <
0.001). Similar results were obtained when the HER2 3+ cases
were removed (data not shown).
Distribution of the PAM50 intrinsic subtypes
PAM50 intrinsic subtypes were available from 1,576 (42.7%)
patients. Intrinsic subtypes were differentially distributed among
the three IHC-based groups, as well as between HER2-low and
HER2 0 tumors (p < 0.001 for both) (Fig. 3, Table 1, and
Supplementary Table 1). Intrinsic subtypes distribution varied also
between HR-positive and TNBC (p < 0.001) (Fig. 3 and Supple-
mentary Table 2). Specifically, Luminal A tumors were more
frequent within the IHC 2+ (54.2%), HER2-low (50.8%) and HR-
positive (56.6%) groups compared to IHC 1+ (49.0%), IHC 0
(28.7%) and TNBC (1.6%). Similarly, Luminal B were more frequent
within the IHC 2+ (30.2%), HER2-low (28.8%) and HR-positive
(33.9%) groups compared to IHC 1+ (28.0%), IHC 0 (18.9%) and
TNBC (0.2%); HER2-enriched (HER2-E) were more frequent within
the IHC 0 (5.9%) and TNBC (8.5%) groups compared to IHC 2+
(2.8%), IHC 1+ (4.0%), HER2-low (3.5%) and HR-positive tumors
(3.1%); Basal-like tumors were mostly concentrated within the IHC
0 (43.7%) and TNBC (84.7%) groups compared to IHC 2+ (9.8%),
IHC 1+ (15.2%), HER2-low (13.4%) and HR-positive tumors (3.9%).
Within HR-positive disease, intrinsic subtypes were differentially
distributed between HER2-low and HER2 0 tumors, as well as
according to IHC score (p < 0.001 in both cases; Table 2 and
Supplementary Table 3). Specifically, Luminal B and Basal-like
subtypes were less frequent in HER2-low compared to HER2 0
(Luminal B: 8.0% vs. 34.9%; Basal-like: 1.9% vs. 33.4%), while
Luminal A subtype was more frequent in HER2-low compared to
HER2 0 (58.9% vs. 2.8%). There was no significant difference in
subtype distribution in TNBC according to HER2-low status and
IHC score (p= 0.438 and p= 0.284, respectively; Table 2 and
Supplementary Table 3). When comparing HR-positive and TNBC
according to the same HER2 IHC score, intrinsic subtypes were
significantly differentially distributed, with Basal-like tumors being
the predominant subtype in each TNBC/HER2 subset (85.2% in
HER2 0, 85.4% in HER2 1+, 78.4% in HER2 2+). As expected,
Luminal A (51.8% in HER2 0, 57.9% in HER2 1+, 60.6% in HER2 2+),
followed by Luminal B subtype (34.9% in HER2 0, 33.1% in HER2
1+, 33.8% in HER2 2+), were the most frequent in each HR-
positive/HER2 subset (Supplementary Table 4).
Finally, we investigated if the distribution of PAM50 subtypes
within HER2-low breast cancer differed according to ERBB2 mRNA
levels. To approach it, we divided all patients with HER2-negative
disease into tertiles (i.e., from low to high: T1, T2, and T3) based on
ERBB2 expression (Table 3). As expected, subtype distribution
differed in HER2-low breast cancer according to ERBB2 levels (p <
0.001) with the T2-3 group being more enriched with Luminal A,
Luminal B and HER2-E subtypes (51.5%, 34.9%, and 6.3%)
compared to the T1 group (31.7%, 15.8%, and 3.6%). On the
contrary, the Basal-like subtype was more frequent in the T1 group
compared to the T2-3 group (44.6% vs 2.9%). The results were
similar when comparing either ERBB2 high/HER2-low and ERBB2
low/HER2-low tumors with the whole HER2-low population (p <
0.001 both) (Table 3).
PAM50 and individual gene expression analyses
PAM50 and individual gene expression data was available in 1,320
(35.8%) patients. The full list of genes and subtypes’ signatures
evaluated for differential expression analyses in the overall HER2-
negative population and according to HR status are reported in
Supplementary Table 5.
In the overall population, 34 of 55 genes (61.8%) were found
differentially expressed between HER2-low and HER2 0 (false-
discovery rate [FDR] < 5%) (Table 4, Supplementary Table 6 and
Supplementary Fig. 1). Specifically, 14 genes (41.2%) were found
Table 1 continued
Demographics HER2-negative pa
HER2 0 HER2-low Overall population
N % N % N %
1,486 40.3 2,203 59.7 3,689 100
TILs
Median 1 1 1 0.218
IQR 0–5 1–5 1–5
Min–max 0–80 0–80 0–80
Pts with available data 102 37.2 172 62.8 274 100
PAM50 subtypes
Luminal A 193 28.7 459 50.8 652 41.4 <0.001
Luminal B 127 18.9 260 28.8 387 24.6
HER2-enriched 40 5.9 32 3.5 72 4.6
Basal-like 294 43.7 120 13.3 414 26.3
Normal-like 19 2.8 32 3.5 51 3.1
Total 673 42.7 903 57.3 1,576 100
HR status
HR-positive 1,025 69.6 1,937 88.2 2,962 80.8 <0.001
TNBC 448 30.4 258 11.8 706 19.2
Total 1,473 40.2 2195 59.8 3,668 100
aChi-square test for differences in proportions, Kruskalis–Wallis and Wilcoxon rank sum test with continuity correction, where appropriate, for continuous
variables (median comparisons).
Pts patients, HR hormone receptors, IQR interquartile range, IHC immunohistochemical, TILs tumor-infiltrating lymphocytes.
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significantly downregulated in HER2-low compared to HER2 0,
including proliferation-related genes (e.g., CCNB1, CCNE1, MELK,
MKI67, MYBL2 etc.), Basal-like-related genes (e.g., KRT14, KRT17,
KRT5, FOXC1, MYC etc.), tyrosine-kinase receptors (i.e., EGFR,
FGFR4), and three PAM50 signatures (i.e., HER2-E, Basal-like and
Normal-like). Conversely, 20 genes (58.8%) were found signifi-
cantly upregulated in HER2-low compared to HER2 0, including
luminal-related genes (e.g., BCL2, BAG1, FOXA1, ESR1, PGR, GPR160
and AR) and two PAM50 signatures (i.e., Luminal A and B).
According to HR status, similar findings were observed in HR-
positive disease as in the general population (Table 4, Supple-
mentary Table 6, and Supplementary Fig. 2). In TNBC, however, no
individual gene, or PAM50 signature, was found differentially
expressed between HER2-low and HER2 0. Similar findings were
observed when HER2-low disease was subdivided into 1+ and 2+
(Table 4, Supplementary Table 6, and Supplementary Fig. 3).
Gene expression profiles according to HER2 expression and HR
status
The previous results suggested that HR status is a key determinant
of the underlying biology of HER2-low breast cancer. To further
explore this, we evaluated the overall gene expression profile of
HER2-negative breast cancer according to HER2 expression (i.e.,
HER2 0, 1+ and 2+) and HR status (i.e., positive and negative). The
result clearly shows that HR status is the main driver of the
underlying biology (Fig. 4 and Supplementary Table 7). As
expected, proliferation-related genes (e.g., CCNE1, MKI67 and
EXO1) were found more expressed in TNBC compared to HR-
positive, regardless of HER2 IHC status (i.e., HER2-low vs. HER2 0).
On the contrary, luminal-related genes (e.g., ESR1, AR, and BCL2)
and ERBB2 were found more expressed in HR-positive compared
to TNBC, regardless of HER2 IHC status. Of note, the highest ERBB2
expression was found in the HR-positive/HER2-low group. Finally,
concordant with the previous results, HER2-low tumors within HR-
positive disease showed a relatively lower expression of
proliferation-related genes and higher expression of luminal-
related genes compared to the HER2 0 group (Supplementary
Fig. 4 and Supplementary Table 8).
ERBB2 expression analysis
The previous observation that ERBB2 levels differ according to
HER2 IHC expression (HER2 0, 1+, and 2+) and HR status was
somewhat unexpected. To further explore this finding, we formally
compared the abundance of ERBB2 in HR-positive disease and
TNBC based on HER2 IHC expression. ERBB2 levels were
statistically significantly higher in HR-positive tumors compared
Fig. 3 Intrinsic subtype distribution according to HER2 status and HR status. HR hormone receptors, TNBC triple-negative breast cancer,
IHC immunohistochemistry, ISH in situ hybridization (including either FISH, SISH, and CISH). Number of patients in A (n= 1576), B (n= 1137);
C (n= 437); D (n= 673); E (n= 701); F (n= 325).
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to TNBC regardless of HER2 IHC expression (p < 0.001; Fig. 5A, B).
Within HR-positive disease, ERBB2 levels were significantly higher
in HER2-low tumors compared to HER2 0 (1.4-fold mean
difference, p < 0.001, Fig. 5C), with the highest amount observed
in HER2 IHC 2+ tumors, followed by 1+ and 0 (Fig. 5D), in
decreasing order (1.7-fold mean difference between HER2 2+ vs.
HER2 0). Within TNBC, there was no statistically significantly
difference in ERBB2 levels across the three HER2 IHC groups (p=
0.080, Fig. 5E); however, TNBC/HER2-low tumors showed statisti-
cally significantly higher levels of ERBB2 compared to HER2 0
tumors (p= 0.027), although the absolute mean difference was
very small (Fig. 5F).
Prognosis of HER2-low in advanced HER2-negative breast cancer
We conducted an exploratory overall survival (OS) analysis in 1,304
patients with advanced breast cancer across two datasets (i.e.,
Memorial Sloan Kettering Cancer Center database18 and Hospital
Clinic internal database). OS was defined from the date of the first
diagnosis of breast cancer. The median follow-up for the overall
population was 90.3 months (95% confidence interval [CI]:
84.6–99.4). In all patients, no statistically significantly differences
in OS were observed between the HER2-low and HER2 0 groups
(p= 0.787). Similar results were obtained according to HR status
and HER2 IHC levels (Fig. 6).
DISCUSSION
Our results provide preliminary insights of the clinical and
molecular characteristics of HER2-low breast cancer. According
to our results, patients with HER2-low disease represent the vast
majority (59.7%) of patients with HER2-negative tumors. Clinically,
HER2-low breast cancer is apparently more frequent in older and
male patients and shows more axillary lymph-node involvement
compared to HER2 0 disease. Importantly, we observed that HR
status has an important role in HER2-low disease. For example, the
frequency of HER2-low disease is higher in HR-positive breast
cancer than TNBC (65.4% vs. 36.6%) and most HER2-low tumors
Table 2. PAM50 intrinsic subtypes distribution within HR-positive and TN tumors according to HER2 status.
HR-positive HER2 0 HER2-low Overall pa
N % N % N %
PAM50 subtypes
Luminal A 187 51.8 457 58.9 644 56.6 <0.001
Luminal B 126 34.9 259 33.4 385 33.9
HER2-enriched 12 3.3 23 3.0 35 3.1
Basal-like 29 8.0 15 1.9 44 3.9
Normal-like 7 1.9 22 2.8 29 2.6
Total 361 31.8 776 100.0 1,137 100.0
TNBC
PAM50 subtypes
Luminal A 5 1.6 2 1.6 7 1.6 0.438
Luminal B 1 0.3 0 0.0 1 0.2
HER2-enriched 28 9.0 9 7.1 37 8.5
Basal-like 265 85.2 105 83.3 370 84.7
Normal-like 12 3.9 10 7.9 22 5.0
Total 311 71.2 126 100.0 437 100.0
HR hormone receptor, TNBC triple-negative breast cancer.
aChi-square test for differences in proportions.
Table 3. Intrinsic subtypes distribution in HER2-low tumors according to ERBB2 mRNA levels.
Intrinsic subtype ERBB2 high (T3-T2) ERBB2 low (T1) HER2-low pa pb pc
N % N % N %
Luminal A 140 51.5 44 31.7 184 44.8 <0.001 <0.001 <0.001
Luminal B 95 34.9 22 15.8 117 28.5
HER2-enriched 17 6.3 5 3.6 22 5.4
Basal-like 8 2.9 62 44.6 70 17.0
Normal-like 12 4.4 6 4.3 18 4.4
Total 272 66.2 139 33.8 411 100.0
ERBB2 is italicized, as per standard gene ID formatting guidelines. T1: tertile one; T2: tertile two; T3: tertile 3.
aReferred to the comparison between ERBB2 high vs. low.
bReferred to ERBB2 high vs. the overall HER2-low population.
cReferred to ERBB2 low vs. the overall HER2-low population.
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are HR-positive (88.2%) or Luminal A or B (79.6%). Another
important result of our study is that the vast majority (67.6%) of
HER2-low tumors have an IHC 1+ score, regardless of HR status.
Interestingly, when HR-positive disease and TNBC are divided
according to the HER2 IHC score, no significant difference in
subtype distribution is observed in TNBC, which was characterized
by a high prevalence of the Basal-like subtype (84.7%), followed by
the HER2-E (8.5%) subtype. On the contrary, HR-positive/HER2-low
tumors appeared to be characterized by a higher proportion of
luminal subtypes compared to HER2 0 tumors. Of note, the HER2-E
subtype was infrequent and similarly distributed in HER2-low and
HER2 0 breast cancer.
As expected, the differences in subtype distribution according
to HER2 IHC expression and HR status are consistent with the
observed changes in expression of individual genes. For example,
the vast majority of proliferation-related genes and tyrosine-kinase
receptor genes are found more expressed in HER2 0 tumors
compared to HER2-low tumors, while HER2-low tumors have more
expression of luminal-related genes. This finding is especially
relevant in HR-positive disease. On the contrary, no clear biological
differences are observed in TNBC according to HER2 IHC
expression. Overall, these findings suggest that HR-positive/
HER2-low tumors are a more distinct biological entity compared
to TNBC/HER2-low tumors.
The lack of enrichment of the HER2-E subtype within HER2-low
disease is intriguing and somewhat unexpected. However,
previous studies have shown that the HER2-E phenotype is not
defined by the expression of a single gene such as ERBB2. In fact,
we and others have previously shown that the two variables (i.e.,
HER2-E subtype and ERBB2 levels) provide independent predictive
and prognostic information19. Overall, this finding clearly high-
lights the need to separate expression of single genes or receptors
from the underlying tumor phenotype.
Recent studies have opened up a new therapeutic scenario by
showing potent activity of HER2-targeted novel ADCs in HER2-low
breast cancer8. To date, T-DXd, a trastuzumab conjugated to eight
molecules of deruxtecan, a topoisomerase I inhibitor, is at the
most advanced in clinical development. A recently published
phase Ib study enrolling highly pretreated patients with advanced
HER2-expressing/mutated solid tumors, including HER2-low breast
cancer, revealed a remarkable overall response rate (ORR) of 37.0%
(95% CI: 24.3–51.3%) in HER2-low breast cancer and an impressive
median duration of response of 10.4 months (95% CI: 8.8 month—
not evaluable), with no apparent differences in ORR between 1+
and 2+ IHC tumors (35.7% vs. 38.5%)9. Interestingly, the ORR did
seem to differ according to HR status (40.4% in HR-positive disease
and 14.3% in TNBC). This result is concordant with our findings
that ERBB2 levels are more expresses in HR-positive/HER2-low
tumors than in TNBC/HER2-low tumors. A phase III trial specifically
enrolling patients with HER2-low metastatic breast cancer (i.e.,
NCT03734029/DESTINY-Breast04) is ongoing. Importantly, we
previously demonstrated in HER2-positive disease that ERBB2
mRNA levels might provide a better selection of patients that
benefit to the ADC T-DM120. This might also be the case for HER2-
low tumors and might be worth focusing on this aspect in further
studies.
SYD985 is another ADC comprises trastuzumab covalently
bound to a linker drug containing duocarmycin. This drug also
showed a promising ORR of 28 and 40% in HR-positive/HER2-low
and TNBC/HER2-low, respectively21. In addition, other anti-HER2
Table 4. Top 20 differentially expressed genes between HER2-low and HER2 0 disease.








ESR1 Higher in HER2-low 14.3 0 5.0 0 1.0 100
FOXA1 Higher in HER2-low 13.3 0 4.9 0 1.0 100
NAT1 Higher in HER2-low 12.3 0 4.1 0 −0.3 68.3
SLC39A6 Higher in HER2-low 11.6 0 4.0 0 −0.4 64.3
PGR Higher in HER2-low 11.2 0 3.2 0 0.5 100
AR Higher in HER2-low 10.6 0 — — 0.4 100
ERBB2 Higher in HER2-low 10.0 0 5.2 0 1.7 100
MAPT Higher in HER2-low 9.9 0 2.9 0 −0.2 68.3
MLPH Higher in HER2-low 8.8 0 2.6 0 0.0 68.3
BCL2 Higher in HER2-low 8.2 0 2.5 0 0.0 68.3
CENPF Lower in HER2-low −7.0 0 −1.8 0 −1.0 64.3
EXO1 Lower in HER2-low −7.1 0 −2.4 0 −1.2 64.3
ANLN Lower in HER2-low −7.4 0 −2.3 0 −0.4 64.3
ORC6L Lower in HER2-low −7.6 0 −2.3 0 −0.8 64.3
KNTC2 Lower in HER2-low −7.8 0 −2.3 0 −0.7 64.3
CEP55 Lower in HER2-low −7.8 0 −1.3 3.2 −1.1 64.3
PHGDH Lower in HER2-low −8.4 0 −1.7 0 −1.2 64.3
FOXC1 Lower in HER2-low −8.4 0 −0.7 9.7 0.2 100
MKI67 Lower in HER2-low −8.7 0 −2.4 0 −1.0 64.3
CCNE1 Lower in HER2-low −9.6 0 −3.0 0 −0.9 64.3
In the table only significantly subtype signatures, top-10 upregulated and top-10 downregulated genes for the overall population are reported, along with
their corresponding result in the HR+ and TNBC populations. Genes are italicized, as per standard formatting guidelines.
HR hormone receptors, TNBC triple-negative breast cancer, FDR false-discovery rate.
aSignificant if FDR < 5.0; Score(d): a T-statistic value that reflects a standardized change in expression and measures the strength of the relationship between
gene expression and the HER2-low category (vs. HER2 0).
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Fig. 4 Gene expression profiles of HER2-negative breast cancer according to HER2 expression and HR status. Supervised clustering of 55
genes across four tumor classes defined according to HER2 IHC expression and HR status. All samples and gene expression data in each
category have been combined into a single group. For each gene in a group, we calculated the standardized mean difference between the
gene’s expression in that class vs. its overall mean expression in the dataset using a 4-class Significance Analyses of Microarrays. The red color
represents relative high gene score, green represents relative low gene score, and black represents median gene score. HR-positive hormone
receptor positive, TNBC triple-negative breast cancer.
F. Schettini et al.
8
npj Breast Cancer (2021)     1 Published in partnership with the Breast Cancer Research Foundation
ADCs (i.e., PF-06804103, MEDI4276, and XMT-1522) have shown
promising activity in HER2-low tumors in the preclinical setting8,22,
and phase 1 clinical trials are ongoing (clinicaltrials.gov identifier:
NCT03284723, NCT02564900, and NCT02952729, respectively).
Tumors with high ERBB2 mRNA levels, but overall HER2-
negative, might also benefit from novel tumor vaccines targeted
against the HER2 protein, as shown by a recent randomized
phase II trial of HER2-targeted vaccine nelipepimut-S combined
with trastuzumab as adjuvant treatment in HER2-low high-risk
breast cancer23. In this direction, we observed higher levels of TILs
in the HER2 2+ group compared to the HER2 0 and 1+ groups,
although this analysis was based on a very restricted number of
cases. Further studies are needed to study the immune compart-
ment of HER2-low breast cancer.
Our study presents limitations that need attention. First, we
retrospectively combined patients from databases pertaining to
different studies, with different original purposes and inclusion/
exclusion criteria; therefore, patients were not consecutively
Fig. 5 ERBB2 mRNA levels within the overall, HR-positive and TNBC populations according to HER2-low expression. Relative transcript
abundance of ERBB2 (HER2 gene) within the overall population (n= 871) and within HR-positive disease (n= 494) and TNBC (n= 377)
according to HER2 IHC-based expression. The boxes represent the interquartile range (25th and 75th percentiles), and the horizontal line in
the box represents the median value. The whiskers show the range of largest and smallest values. HR-positive hormone receptor positive,
TNBC triple-negative breast cancer.
F. Schettini et al.
9
Published in partnership with the Breast Cancer Research Foundation npj Breast Cancer (2021)     1 
enrolled and a large proportion of them had metastatic disease.
These might explain some of the imbalances that we observed
between groups. Additionally, HER2 IHC status was not evaluated
centrally; thus, inter-pathologist variability might have affected the
results. Moreover, criteria for defining negative or equivocal ERBB2
amplification have changed over time1,2 and most ERBB2
amplification results were only available in qualitative form (i.e.,
amplified, not amplified or equivocal). Another limitation is that
we did not address intra-tumor HER2 heterogeneity, which
represents 1%–34% of all breast tumors24 and has clinical and
prognostic implications, with poor response to anti-HER2-based
regimens and worse prognosis, compared to HER2-positive
tumors24. However, this feature is more common in HER2
equivocal disease24, a condition that was an exclusion criteria in
our study, somewhat mitigating this issue. Finally, we limited our
genomic analysis to the PAM50 genes and five additional genes.
Thus, broader genomic analyses are likely to shed more light on
this topic.
To our knowledge, this is the first comprehensive study focused
specifically on HER2-low breast tumors. We provided extensive
comparisons among the three different IHC-based classes of
HER2-negative breast cancer and according to HR status. We
found that HER2-low breast tumors are complex and hetero-
geneous, with no specific prognostic implications and HR-positive/
HER2-low emerge as a more distinct biological entity compared to
the other groups. In addition, the evidence of ERBB2 levels being
higher in HER2-low/HER2 2+ tumors (especially in the HR-positive)
compared to HER2 1+ /0 is in line with some previous findings
from single institutions-based studies, and contributes to reassure
about the reliability of our results25,26. Similarly, the high
prevalence of luminal disease in HER2-low disease has also been
observed in other studies24. Finally, the concordance analysis of
HER2 scoring by different pathologists showed an almost perfect
agreement for HER2 0 and 3+ scores; however, the agreement for
the HER2 1+ and 2+ categories was only substantial, according to
Landis and Koch interpretation27. This result clearly suggests that
more efforts are needed to standardize the scoring of HER2-low
disease and potentially implement new and more sensitive assays




All non-overlapping publicly available breast datasets (i.e., 12 studies and
6477 patients) were interrogated from the cBio Cancer Genomics Portal
(http://cbioportal.org). From these databases, HER2-negative tumors with
known IHC and HER2 amplification status were extracted10–13. Other
patients were extracted from internal databases from the Hospital Clinic
(Barcelona, Spain), from two SOLTI clinical trials (SOLTI 1501-VENTANA and
SOLTI 1402-CORALEEN)14,15, from the Spanish Cancer Research Group
(GEICAM)/CIBOMA study16 and from a previously published collaboration
between Hospital Clinic (Barcelona, Spain), Hospital Vall d’Hebron
(Barcelona, Spain), University Campus Bio-Medico (Roma, Italy) and
GEICAM17 (see Supplementary Table 9 for study details). All studies had
received proper ethical approval by the local institutional research ethics
Fig. 6 Overall survival in patients with advanced HER2-negative breast cancer according to HER2 expression. The figure shows
Kaplan–Meier curves of overall survival for HER2-low vs HER2 0 tumors in the HR-positive (A) and TNBC (C) populations, as well as OS curves
for HER2 2+ vs. HER2 1+ vs. HER2 0 tumors for the HR-positive (B) and TNBC (D) populations with number at risk shown at the bottom of each
box. p-values for log-rank tests are also reported; HR-positive hormone receptor positive, TNBC triple-negative.
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committee of all participating institutions and patients had given their
consent to participate.
Inclusion criteria
Patients were included if they were HER2-negative with known IHC and
HER2 amplification status and if they had at least one of the following
information available: (1) clinicopathological features, (2) PAM50 gene
expression data, and (3) PAM50 intrinsic subtype identified. The following
clinical-pathological features were evaluated, when available: Ki67 IHC,
histological grade, estrogen receptor and progesterone receptor status,
age at diagnosis, menopausal status, tumor sample origin (primary vs.
metastatic), histological subtype and TILs.
IHC-based classification
Tumors were divided into HR-positive (i.e., ER and/or PgR ≥1%) or
TNBC, defined as ER < 1% and PgR<1%. In addition, tumors were
classified into HER2 0, in case of an IHC score of 0, and HER2-low,
defined as HER2 IHC of 1+ or 2+ with an HER2 amplification negative
result by in situ hybridization (ISH) techniques. HER2 IHC 0 and 1+ were
considered HER2 0 and HER2-low, respectively, unless ISH-based data
was available and reported as HER2-amplified. HER2 status in each
cohort had been previously determined using standard FDA-approved
antibodies and ISH-techniques and classified according to the ASCO/
CAP guidelines1,2. Whenever available, we interpreted ISH-derived
HER2/CEP17 ratio value and ERBB2 copy number results jointly with
HER2 IHC score, according to last ASCO/CAP guidelines1. More
specifically, tumors with an average HER2 copy number <4.0 signals/
cell, were considered HER2-negative, and also HER2-low in case of an
IHC score of 1+ or 2+, irrespective of the HER2/CEP17 ratio. However, if
the HER2/CEP17 ratio was ≥2.0 and HER2 IHC 3+, tumors were
considered HER2-positive and excluded1.
In case of available average HER2 copy number ≥4.0 and <6.0 signals/
cell without HER2/CEP ratio and an IHC 3+, the tumor was considered
positive and excluded. In case of IHC 0 or 1+, the tumor was considered
HER2-negative, and also HER2-low in the latter case1. In case of IHC 2+,
considering the unfeasibility of a retesting, in our case, if the categorization
HER2-positive/negative was available from the original dataset, it was
adopted and the tumor was considered HER2-negative and HER2-low. If
the categorization was not provided, the sample was excluded.
In case of IHC score 0, 1+ or 2+, and a concurrent average HER2 copy
number ≥4.0 and <6.0 signals/cell, with HER2/CEP17 ratio <2.0, the tumor
was considered HER2-negative, and HER2-low in the last two cases. On the
contrary, if the HER2/CEP17 watio was ≥2.0, the tumor was considered
HER2-positive and excluded1.
In case of HER2 copy number ≥6.0 signals/cell, the tumor was
considered HER2-positive and excluded in case of IHC of 2+ or 3+,
regardless of the HER2/CEP17 ratio result, but in case of HER2/CEP17 ratio
<2.0 and IHC 0 or 1+, the tumor was considered negative, and also HER2-
low in the second case1.
Patients with a persistent HER2 equivocal result were excluded1.
To evaluate the concordance of the HER2 IHC categories among
pathologists, we performed an inter-pathologist concordance analysis
across 100 independent cases of HER2 staining (HER2 0, 1+, 2+, and 3
+). Five independent breast cancer-specialized pathologists (i.e., BG, ES,
RF, VP, and GP) from four institutions (i.e., Hospital Clinic, VHIO, HVH,
and Campus Bio-Medico) were involved. Blinded scores were provided
to FS and AP, who performed the concordance analysis.
PAM50 subtypes and gene expression data
We obtained PAM50 subtype information and individual gene expression
data from 9 of the 13 retrospective cohorts (Hospital Clinic internal series,
SOLTI and GEICAM trials reported in Supplementary Table 9). An nCounter-
based research version of PAM50 had been previously used28,29. Intrinsic
subtypes and raw gene expression data had been obtained from formalin-
fixed paraffin-embedded (FFPE) tumor samples. For RNA purification
(Roche High Pure FFPET RNA isolation kit), at least 1 to 3 10-μm FFPE slides
had been used for each tumor specimen, and macrodissection performed,
when needed, to avoid normal breast tissue contamination. A minimum of
~150 ng of total RNA had been used to measure the expression of 50
breast cancer-related genes, 4 immune-related genes, androgen receptor
gene (full gene list included in Supplementary Table 5), and 5 house-
keeping genes (ACTB, MRPL19, PSMC4, RPLP0, and SF3A1) using the
nCounter platform (NanoString Technologies, Seattle WA)28,30. Data had
been log base 2 transformed and normalized using the five housekeeping
genes. Intrinsic subtyping (Luminal A, Luminal B, HER2-E, Basal-like and
Normal-like) had been previously performed using the research-based
PAM50 intrinsic subtype predictor29. We also retrieved intrinsic subtypes
from the publicly available TCGA database (see “Data availability” section
for further information).
Statistical analysis
Patient and tumor characteristics were analyzed using chi-square (χ2) test,
Fisher’s exact test, Kruskalis–Wallis and Wilcoxon rank sum test with
continuity correction, where appropriate. The concordance analysis among
pathologists was performed using the Fleiss’ Kappa. The agreement
among pathologists was considered poor for k < 0, low for k= 0.01–0.20,
fair for k= 0.21–0.40, moderate for k= 0.41–0.60, substantial for k=
0.61–0.80, and almost perfect for k= 0.81–1.0027.
All differences were considered significant at p < 0.05. Bonferroni–Holm
method was used to control the family-wise error rate in case of multiple
comparisons.
OS was evaluated for patients with homogeneous follow-up with
available or computable survival data. Such patients pertained to the
Memorial Sloan Kettering Cancer Center (MSKCC)’s subset of the cBio
Cancer Genomics Portal group and to the Hospital Clinic of Barcelona
subset. All patients were affected by metastatic disease and presented
available information regarding primary tumor diagnosis.
The OS distributions were estimated using the Kaplan–Meier method
and the log-rank test was used to assess the difference in survival
distribution between the groups31. Censoring was done at the date of last
available follow-up. Significance Analysis of Microarray (SAM) for unpaired
samples (multiclass and two class) was used to compare gene expression
profiles between groups32. Differences were considered significant at an
FDR < 5%. All analyses were performed with R version 3.6.133, Cluster 3.0,
Javatreeview 1.1.6r434 and Microsoft Excel.
Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
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